DNA SOLUTIONS

ww.dnasolutions.com

DNA Solutions have been assisting individuals around the globe with DNA Paternity & relationship analysis & were the first pioneering company offering DNA home kits to test for paternity and introduced these back in the 90’s. Many of our technical staff and management are ex-police and ex-military DNA testing forensic scientists, further enhancing the quality and range of our DNA tests. Processing occurs in our own DNA laboratory, our lab is capable of DNA ancestry testing, paternity testing, relationship tests, DNA banking and preservation, where we additionally carry out extensive research and development. We have offices and laboratories worldwide & serve thousands of individuals and organizations globally

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

news image

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More

Industrial Impact, Diagnostics

ABCELLERA AND RQ BIO PARTNER TO ACCELERATE THE ADVANCEMENT OF NEW THERAPIES FOR INFECTIOUS DISEASE

businesswire | March 23, 2023

news image

AbCellera and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly po...

Read More

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

news image

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris | October 23, 2020

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More
news image

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More
news image

Industrial Impact, Diagnostics

ABCELLERA AND RQ BIO PARTNER TO ACCELERATE THE ADVANCEMENT OF NEW THERAPIES FOR INFECTIOUS DISEASE

businesswire | March 23, 2023

AbCellera and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly po...

Read More
news image

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More
news image

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris | October 23, 2020

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More